Home›Axitinib

Axitinib

Kinase InhibitorReceptor Tyrosine Kinase Inhibitors

Route: Oral

18 interactions on record

Axitinib has 18 known drug interactions based on U.S. FDA drug labeling data. 13 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carbamazepine, Dexamethasone, Grapefruit Juice. Patients taking Axitinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 18
Major: 13
Moderate: 5

Major (13)

Axitinib + Carbamazepine— Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.
Axitinib + Dexamethasone— Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.
Axitinib + Grapefruit Juice— May increase axitinib plasma concentrations and should be avoided.
Axitinib + Grapefruit Products— May increase axitinib plasma concentrations and should be avoided.
Axitinib + Itraconazole— Antineoplastics irinotecan axitinib, dabrafenib, dasatinib, ibrutinib, nilotinib, sunitinib bortezomib, busulphan, docet…
Axitinib + Ketoconazole— Strong CYP3A4/5 inhibitor increases axitinib plasma exposure. Co-administration should be avoided; if unavoidable, reduc…
Axitinib + Phenobarbital— Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.
Axitinib + Phenytoin— Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.
Axitinib + Rifabutin— Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.
Axitinib + Rifampin— Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.
Axitinib + Rifapentine— Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.
Axitinib + St. John'S Wort— Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.
Axitinib + Voriconazole— Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabr…

Moderate (5)

Axitinib + Bosentan— Moderate CYP3A4/5 inducer may reduce axitinib plasma exposure and should be avoided if possible.
Axitinib + Efavirenz— Moderate CYP3A4/5 inducer may reduce axitinib plasma exposure and should be avoided if possible.
Axitinib + Etravirine— Moderate CYP3A4/5 inducer may reduce axitinib plasma exposure and should be avoided if possible.
Axitinib + Modafinil— Moderate CYP3A4/5 inducer may reduce axitinib plasma exposure and should be avoided if possible.
Axitinib + Nafcillin— Moderate CYP3A4/5 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, and nafcillin) may also reduce the plasma …

Axitinib + Carbamazepine⚠️Major

Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.

Axitinib + Dexamethasone⚠️Major

Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.

Axitinib + Grapefruit Juice⚠️Major

May increase axitinib plasma concentrations and should be avoided.

Axitinib + Grapefruit Products⚠️Major

May increase axitinib plasma concentrations and should be avoided.

Axitinib + Itraconazole⚠️Major

Antineoplastics irinotecan axitinib, dabrafenib, dasatinib, ibrutinib, nilotinib, sunitinib bortezomib, busulphan, docetaxel, erlotinib, imatinib, ixabepilone, lapatinib, ponatinib, trimetrexate, vinca alkaloids Irinotecan: The potential increase in plasma concentrations of irinotecan when coadministered with itraconazole may increase the risk of potentially fatal adverse events.

Axitinib + Ketoconazole⚠️Major

Strong CYP3A4/5 inhibitor increases axitinib plasma exposure. Co-administration should be avoided; if unavoidable, reduce axitinib dose.

Axitinib + Phenobarbital⚠️Major

Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.

Axitinib + Phenytoin⚠️Major

Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.

Axitinib + Rifabutin⚠️Major

Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.

Axitinib + Rifampin⚠️Major

Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.

Axitinib + Rifapentine⚠️Major

Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.

Axitinib + St. John'S Wort⚠️Major

Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.

Axitinib + Voriconazole⚠️Major

Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of VFEND.

Axitinib + Bosentan🟡Moderate

Moderate CYP3A4/5 inducer may reduce axitinib plasma exposure and should be avoided if possible.

Axitinib + Efavirenz🟡Moderate

Moderate CYP3A4/5 inducer may reduce axitinib plasma exposure and should be avoided if possible.

Axitinib + Etravirine🟡Moderate

Moderate CYP3A4/5 inducer may reduce axitinib plasma exposure and should be avoided if possible.

Axitinib + Modafinil🟡Moderate

Moderate CYP3A4/5 inducer may reduce axitinib plasma exposure and should be avoided if possible.

Axitinib + Nafcillin🟡Moderate

Moderate CYP3A4/5 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, and nafcillin) may also reduce the plasma exposure of axitinib and should be avoided if possible.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.